Twitter   LinkedInFacebook RSS  
  • MME
  • BRCA
  • DXX-1
  • Cell Culture
  • DXX-2
  • Roche-sequencer
  • DXX-3
Matchmaker Exchange Networks Genetic Databases For Rare Disease Diagnosis
|

Diagnostics World | Matchmaker Exchange (MME) aims to create a network that connects several isolated rare disease databases using a common application programming interface (API) that supports queries and responses. If it can provide researchers and clinicians with data from just one more case with a deleterious variant in the same gene and phenotypic features in common, MME may offer sufficient evidence to identify the causative gene for a specific rare disease.

more

Quest Diagnostics scoops up Safeway partnership after Theranos fallout
| Becker's Hospital Review | Madison, N.J.-based Quest Diagnostics announced a partnership last week with grocery chain Safeway that will bring diagnostic testing to 12 grocery stores in California, Colorado, Texas, Virginia and Maryland. more

IBM Watson Health Launches Imaging Effort for Cancer Other Diseases
| Xconomy | So far, the story of IBM Watson Health has been mostly about growth and potential. Today, it's more about action. The healthcare computing giant is unveiling a collaborative effort in medical imaging that includes partnerships with health systems, radiology providers, tech companies, and academic medical centers. more

Kailos, Huntsman Cancer Institute Collaborate on Breast Cancer Clinical Grade Circulating Tumor Test
| Diagnostics World | Kailos Genetics and the Huntsman Cancer Institute (HCI) at the University of Utah have won a $2.4 million grant from the National Institutes of Health to develop a clinical-grade test for circulating tumor DNA (ctDNA) to monitor patients for breast cancer disease recurrence. more

Diagnostics Companies on Top 50 List
| MIT Technology Review | The Tech Review editors pick the 50 companies that best combine innovative technology with an effective business model. Several diagnostics and biotech companies make the list, including T2 Biosystems (#34), Oxford Nanopore (#22), and Veritas (#40). more

FDA Grants Emergency Use Authorization to Zika Diagnostic
| Diagnostics World News | On Friday, the U.S. Food and Drug Administration (FDA) granted emergency use authorization for Hologic’s new, diagnostic assay for Zika virus infection. more

Something May Be Working At Theranos But You Dont Know What It Is
| Forbes | Elizabeth Holmes speaking at the Forbes Healthcare Summit last December. Credit: Glen Davis If there is working technology at Theranos, the embattled startup that promised to revolutionize blood tests by replacing needles in veins with finger pricks at a lower price with faster speed, you wouldn't be able to tell. To [...] more

An Epidemic of Septicemia?
| THCB | CDC says that 86% of healthcare dollars are spent on patients with chronic illness, and the largest, fastest, and most preventable diagnosis is the most acute of all: septicemia. 13% of the time, patients die. more

Could CRISPR gene-cutting tool transform disease diagnostics?
| STAT | The gene-editing technique CRISPR has been used for the first time to create a diagnostic that can differentiate between two strains of the Zika virus. more

Walgreens Finally Walked. Heres Why Thats So Bad For Theranos
| Forbes | Yesterday, Walgreens, the U.S. drug-store arm of global pharmacy giant Walgreens Boots Alliance, finally terminated its deal with Theranos, the blood-testing startup that once aimed to disrupt the laboratory business but now is fighting for its survival. more


CHI Announces the Inaugural DNA Forensics Conference, August 23-24, 2016, Washington, DC
| NEEDHAM, MA, UNITED STATES - May 26, 2016 - Cambridge Healthtech Institute (CHI) announces its inaugural DNA Forensics conference will take place on August 23-24, 2016 at the Hyatt Washington Hotel in Washington, DC-as part of the Next Generation Dx Summit more

Quanterix Opens Call for Proposals for Second Annual Accelerator Grant Program Focused on Oncology and Liquid Tumor Biopsy Technology
| BOSTON, MA, UNITED STATES - May 20, 2016 - Quanterix Corporation, a leader in the transformation of healthcare through its ultrasensitive single molecule testing capabilities, today announced the recipient of its first annual Accelerator Grant Program and a call for proposals for its second grant, focused on oncology research more

Definiens’ Symposium Finds Tissue Context of Tumor is Key to Cancer Immunotherapy Success
| MUNICH, GERMANY - May 10, 2016 - Definiens, the pioneer in Tissue Phenomics® solutions for diagnostics development, has announced findings from the International Symposium, a sold-out gathering of international researchers and clinicians on April 27-28 in Boston, Massachusetts to discuss advancements in oncology and the application of Tissue Phenomics more

Novigenix publishes multi-center study of Colox(R) in Clinical Cancer Research
| LAUSANNE, SWITZERLAND - May 9, 2016 - Novigenix SA today announced the publication of a clinical validation study of Colox in the highly ranked journal  Clinical Cancer Research more

BARTS PATIENT DATA DEMONSTRATES POTENTIAL OF PARSORTIX FOR PROSTATE CANCER DETECTION CLINICAL APPLICATION
| LONDON, UK - Mar 21, 2016 - ~~For immediate release  21 March 2016 ANGLE plc (“the Company”) BARTS PATIENT DATA DEMONSTRATES POTENTIAL OF PARSORTIX FOR PROSTATE CANCER DETECTION CLINICAL APPLICATION Potential for a simple blood test to not only detect prostate cancer but also to assess the aggressiveness of the disease allowing risk stratification to active surveillance or intervention ANGLE plc (AIM:AGL OTCQX:ANPCY), the specialist medtech company, is delighted to announce that the results of Barts Cancer Institute’s ongoing work with ANGLE’s Parsortix system have provided evidence in support of the use of Parsortix in the detection and assessment of prostate cancer more

Definiens Launches Immunoprofiling Panel to Rapidly Screen Tissue Samples for Immune Responses
| MUNICH, GERMANY - Mar 8, 2016 - Definiens, the pioneer in Tissue Phenomics solutions for diagnostics development and commercialization, today announced the release of a new service, the Immunoprofiling Panel, to enable pharmaceutical companies, companion diagnostic developers and academic research centers working in immuno-oncology to quickly screen their target biomarkers and measure immune response more

IMMray™ PanCan-d detects 98% of pancreatic cancers in retrospective study with 1400 blood samples
| LUND, SWEDEN - Dec 4, 2015 -     LUND, Sweden  ― CREATE Health Translational Cancer Center, Lund, Sweden in collaboration with Immunovia today announced that they have completed a retrospective study demonstrating that the IMMray™ PanCan-d test is able to differentiate with 96% accuracy patients with  early resectable stages of pancreatic cancer, stage I and II, from the healthy controls more

Insight Pharma Reports Announces Biomanufacturing Capacity Strategies: Developing a Flexible, Scalable and lean Biomanufacturing system
| NEEDHAM, MA, UNITED STATES - Oct 14, 2015 - For more information:Dan MillerInsight Pharma Reportsdmiller@healthtech.com781-972-5492 FOR IMMEDIATE RELEASE Insight Pharma Reports Announces Biomanufacturing Capacity Strategies: Developing a Flexible, Scalable and lean Biomanufacturing system
NEEDHAM, MASS more

Insight Pharma Reports’ The Human Microbiome Report
| NEEDHAM, MA, UNITED STATES - Jun 19, 2015 - Insight Pharma Reports' releases the report, The Human Microbiome: Biomedical Implications and Birth of a Market, which covers the evolution of microbiome research and its growth in the commercial market more

Insight Pharma Reports Releases Marketing to Life Scientists Study
| NEEDHAM, MA, UNITED STATES - Jun 19, 2015 - Insight Pharma Reports, a division of Cambridge Healthtech Institute, releases a new market study focusing on marketing to life scientists more



Lead Generation




For reprints and/or copyright permission, please contact Angela Parsons, 781.972.5467.